Back to overview
SNCTP000004934 | NCT05522205 | BASEC2021-01670

WeedCare - Studie zum regulierten Cannabisverkauf in Basel

Data source: BASEC (Imported from 23.02.2024), WHO (Imported from 15.02.2024)
Changed: Dec 23, 2023, 4:54 PM
Disease category: Other, Mental and Behavioural diseases

Brief description of trial (Data source: BASEC)

Die Studie möchte untersuchen, wie sich der regulierte Cannabisverkauf in Apotheken auf das Konsumverhalten und die Gesundheit von Cannabiskonsumierenden auswirkt im Vergleich zur aktuellen Situation, in welcher Cannabis illegal erhältlich ist. Sofern alle Einschlusskriterien erfüllt sind, werden die Studienteilnehmenden zufällig einer von zwei Gruppen zugeteilt: Grupp1 hat sofortiger Zugang zum Cannabisverkauf in Apotheken. Gruppe 2 hat erst nach 6 Monaten Verzögerung Zugang zum regulierten Cannabisverkauf. Nach sechs Monaten haben alle Studienteilnehmende Zugang zum regulierten Cannabisverkauf.

Health conditions investigated(Data source: BASEC)

Gesundheitliche Auswirkungen des regulierten Cannabisverkaufs

Health conditions (Data source: WHO)

Cannabis Use Disorder;Mental Health Disorder;Physical Illness

Rare disease (Data source: BASEC)

No

Intervention investigated (e.g. drug, therapy or campaign) (Data source: BASEC)

Der regulierte Cannabisverkauf in basel-städtischen Apotheken.

Interventions (Data source: WHO)

Other: Regulated cannabis access in pharmacies

Criteria for participation in trial (Data source: BASEC)

Mindestens 18 Jahre alt
Cannabiskonsum, d.h. mindestens einmal im Monat während den letzten sechs Monaten (inkl. positive THC-Urinprobe)
Wohnhaft im Kanton Basel-Stadt
Deutsch-Grundkenntnisse

Exclusion criteria (Data source: BASEC)

Schwangere oder stillende Frauen
Aktuelle psychiatrische stationäre Behandlung
Aktuelle schwerwiegende Psychose
Akute Selbstgefährdung
Schwere kognitive Beeinträchtigung
Geplanter Wegzug vom Kanton Basel-Stadt innerhalb der ersten 12 Monate

Inclusion/Exclusion Criteria (Data source: WHO)

Gender: All
Maximum age: N/A
Minimum age: 18 Years

Inclusion Criteria:

- At least 18 years, residence in Basel-Stadt, consuming cannabis at least monthly
during the last 6 months (positive urine sample)

Exclusion Criteria:

- pregnant or breastfeeding, currently suicidal, currently psychotic, current inpatient
psychiatric treatment

Further information on the trial in WHO primary registry

https://clinicaltrials.gov/ct2/show/NCT05522205

Further information on the trial from WHO database (ICTRP)

https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05522205
Further information on trial

Recruitment status

Active, not recruiting

Academic title (Data source: WHO)

WEED CARE - Randomized Controlled Study on Regulated Cannabis Access for Recreational Use in Pharmacies in Basel

Type of trial (Data source: WHO)

Interventional

Design of the trial (Data source: WHO)

Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label).

Phase (Data source: WHO)

N/A

Primary end point (Data source: WHO)

Change in problematic cannabis consumption behaviou

Secundary end point (Data source: WHO)

Change in depression;Change in anxiety;Change in psychosis;Change in physical health

Contact information (Data source: WHO)

Please refer to primary and secondary sponsors

Trial results (Data source: WHO)

Results summary

no information available yet

Link to the results in the primary register

no information available yet

Information on the availability of individual participant data

no information available yet

Trial sites

Trial sites in Switzerland (Data source: BASEC)

Basel

Countries (Data source: WHO)

Switzerland

Contact for further information on the trial

Details of contact in Switzerland (Data source: BASEC)

Marc Walter
+41 56 462 29 10
marc.walter@pdag.ch

Authorisation by the ethics committee (Data source: BASEC)

Name of the authorising ethics committee (for multicentre studies only the lead committee)

Ethikkommission Nordwest- und Zentralschweiz EKNZ

Date of authorisation by the ethics committee

12.05.2022

Further trial identification numbers

Trial identification number of the ethics committee (BASEC-ID) (Data source: BASEC)

2021-01670
Back to overview